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Purpose: Recessive mutations of the myosin VIIA (MYO7A) gene are reported to be responsible for both a deaf–blindness
syndrome (Usher type 1B [USH1B] and atypical Usher syndrome) and nonsyndromic hearing loss (HL; Deafness,
Neurosensory, Autosomal Recessive 2 [DFNB2]). The existence of DFNB2 is controversial, and often there is no
relationship between the type and location of the MYO7A mutations corresponding to the USH1B and DFNB2 phenotype.
We investigated the molecular determinant of a mild form of retinopathy in association with a subtle splicing modulation
of MYO7A mRNA.
Methods: Affected members underwent detailed audiologic and ocular characterization. DNA samples from family
members were genotyped with polymorphic microsatellite markers. Sequencing of MYO7A was performed. Endogenous
lymphoid RNA analysis and a splicing minigene assay were used to study the effect of the c.1935G>A mutation.
Results: Funduscopy showed mild retinitis pigmentosa in adults with HL. Microsatellite analysis showed linkage to
markers in the region on chromosome 11q13.5. Sequencing of MYO7A revealed a mutation in the last nucleotide of exon
16 (c.1935G>A), which corresponds to a substitution of a methionine to an isoleucine residue at amino acid 645 of the
myosin VIIA. However, structural prediction of the molecular model of myosin VIIA shows that this amino acid
replacement induces only minor structural changes in the immediate environment of the mutation and thus does not alter
the overall native structure. We found that, although predominantly included in mature mRNA, exon 16 is in fact
alternatively spliced in control cells and that the mutation at the very last position is associated with a switch toward a
predominant exclusion of that exon. This observation was further supported using a splicing minigene transfection assay;
the c.1935G>A mutation was found to trigger a partial impairment of the adjacent donor splice site, suggesting that the
unique change at the last position of the exon is responsible for the enhanced exon exclusion in this family.
Conclusions: This study shows how an exonic mutation that weakens the 5′ splice site enhances a minor alternative
splicing without abolishing a complete exclusion of the exon and therefore causes a less severe retinitis pigmentosa than
the USH1B-associated alleles. It would be interesting to examine a possible correlation between intrafamilial phenotypic
variability and the subtle variation in exon 16 inclusion, probably related to genetic background specificities.
Myosin VIIA, an unconventional myosin, is a member of
a large superfamily of actin-associated molecular motors. It is
composed of a structurally conserved head, neck, and tail
regions. The latter binds actin and hydrolyzes ATP to produce
force and movement. Myosin VIIA physiologic function is
best studied in the sensory hair cells of the inner ear and the
retina. In the inner ear, myosin VIIA is required for hair bundle
morphogenesis and mechanotransduction [1,2]. Within the
retina,  myosin  VIIA  localizes  to  the  cilium  of  the
photoreceptors,  to  the  apical  region  of  retinal  pigment
epithelium (RPE) cells, and to melanosome within RPE cells
[3-5].  In  accordance  with  its  expression  pattern  in  retina,
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myosin VIIA regulates opsin and melanosome transports and
the  phagocytosis  of  shed  outer  segments  by  RPEs  [6,7].
Myosin VIIA has been implicated in recessively inherited
Usher  syndrome  type  1B  (USH1B)  [8],  atypical  Usher
syndrome (USH3) [9], nonsyndromic recessive (Deafness,
Neurosensory, Autosomal Recessive 2 [DFNB2]) [10], and
dominant  (DFNA11)  [11]  hearing  loss  (HL).  USH1B  is
clinically characterized by prelingual severe to profound HL,
prepubertal  progressive  retinitis  pigmentosa  (RP),  and
vestibular areflexia. A progressive HL, variable vestibular
problems, and RP are characteristic of USH3. Although the
existence of myosin VIIA (MYO7A) recessive mutations that
are  associated  with  nonsyndromic  HL  phenotype  is  still
controversial, there is evidence of variability in the clinical
onset  and  diagnosis  of  RP  among  patients  with  MYO7A
mutations. In the large Tunisian family used to define the
DFNB2 locus, funduscopy revealed mild RP in five out of 25
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1898affected  persons  with  HL  [12].  In  the  Pakistani  DFNB2
family, one deaf patient (41 years old) had slightly subnormal
rod  and  cone  responses  and  a  suboptimal  quality
electroretinogram (ERG).
Over 130 mutations in MYO7A have been identified and
are listed in the Human Gene Mutation Database, most leading
to a diagnosis of USH1B. Mutations in MYO7A were reported
in  five  families  with  nonsyndromic  recessive  HL.  It  was
hypothesized  that  DFNB2  mutations  cause  a  less  severe
phenotype than the USH1B-associated alleles because the
resulting protein retains some degree of normal function, at
least in retina. This hypothesis was confirmed only in the
DFNB2 Pakistani family. Riazuddin et al. [13] showed that
green fluorescent protein (GFP)-tagged form of myosin VIIa
containing  deletion  p.E1716del  localizes  properly  to
stereocilia in transfected mouse inner ear hair cells, similarly
to  the  wild-type  protein,  which  argues  for  the  residual
functional activity of the altered protein.
Using  genetic  linkage  and  sequencing  analyses,  we
identified a missense mutation (c.1935G>A) in a Tunisian
family segregating nonsyndromic HL. Funduscopy showed
that RP is mild in adult patients. The mutation is located at the
last  nucleotide  of  MYO7A  exon  16.  The  altered  mRNA
displayed a predominant exclusion of exon 16. A functional
analysis using splicing minigene transfection assay further
supported the effect of the mutation on exon exclusion.
METHODS
Family and clinical evaluation: Two deaf individuals from a
Tunisian family were enrolled through a deaf school. During
a home visit, we ascertained additional four deaf individuals
(Figure 1). Informed consent was obtained from patients and
control individuals in accordance with the ethics committee
of the University Hospital of Sfax. Pure tone audiometry was
performed.  Affected  members  underwent  evaluation  for
balance  using  caloric  testing  and  ophthalmological
investigation,  including  fundus  ophthalmoscopy.  Clinical
history and physical examinations of family members ruled
out the implication of environmental factors in the etiology of
HL and RP. Ten ml of blood samples have been taken from
the vein in the antecubital fossa from ten family members.
Immediately, tubes were inverted about 5 times and labeled
with  the  subject  identification  code.  Samples  were
refrigerated to 4 °C for no more than 4 h. Genomic DNA was
extracted  from  whole  blood  following  a  standard  phenol-
chloroform method. Briefly, lymphocytes were incubated in
a solution of Sodium dodecyl sulfate detergent and proteinase
K.  The  DNA  solution  is  first  extracted  with  a  phenol/
chloroform/isoamyl alcohol mixture then precipitated with
100% ethanol. The DNA is pelleted after the precipitation
step, washed with 70% ethanol, and resuspended in Tris-
EDTA buffer.
Microsatellites genotyping and mutation analysis: For each
gene and locus responsible for USH, at least two microsatellite
markers were selected on the basis of their map position and
heterozygosity  coefficient.  Fluorescent  dye-labeled
microsatellite markers were genotyped for all the participating
family  members.  We  used  the  True  Allele  PCR  Premix
(Applied Biosystems, Foster City, CA) for PCR reactions
according  to  the  manufacturer’s  instructions.  Briefly,  we
assembled a 15 ml reaction containing 9 ml true allele PCR
premix, 10 pmole of a mix of forward and reverse primers,
and 50 ng of genomic DNA. PCR conditions were as follows:
11 min at 94 °C followed by 35 cycles, each consisting of 15
s at 94 °C, 15 s at 55 °C, and 30 s at 72 °C, then a final
elongation  at  72  °C.  Fluorescently  labeled  alleles  were
analyzed on an ABI PRISM 3100-Avant automated genetic
analyzer (Applied Biosystems). Genotypes were determined
using the GenScan™ and GenoTyper™ software (Applied
Biosystems).
One affected subject was investigated for the presence of
a mutation in MYO7A. Amplified products of all coding exons
and exon–intron junctions were directly sequenced using an
ABI 3100-Avant automated DNA sequencer and Big Dye
Terminator  Sequencing  V3.1  kit  (Applied  Biosystems).
Screening  of  the  c.1935G>A  mutation  in  the  family  was
performed  using  PCR-restriction  fragment  length
polymorphism.  PCR  amplification  of  a  349  bp  DNA
fragment,  including  exon  16  of  the  MYO7A  gene,  was
performed with the primers MYO7A16F (5′ACC TCC CCT
CCC GCT TCC T3′) and MYO7A16R (5′-GCC CCC CAT
TCC CCA AAG G-3′). PCR products were digested with 10
U of NcoI restriction endonuclease (New England Biolabs,
Ipswich, MA) for 1 h at 37 °C. Digestion of the wild-type
allele yielded two fragments of 223 bp and 126 bp, while the
mutation abolished the NcoI site.
Molecular modeling and prediction of the splice consensus
score: The MYO7A sequence (accession number Q13402 in
the UniProtKB/Swiss-Protdatabase) was submitted to a Basic
Local Alignment Search Tool (BLAST) [14] search against
the structures in the protein data bank (PDB) to find suitable
templates  for  homology  modeling.  The  myosin  II  motor
domain from Dictyostelium discoideum was found to be the
best homolog, with 42% amino acid sequence identity (PDB
1d0x,  2.0  Å  resolution  [15])  for  the  query  search.  The
alignment of the myosin VIIa sequence against the template
sequence was used as input to the MODELER program [16],
together  with  the  atomic  coordinates  of  the  latter.  Fifty
homology  models  were  built  by  MODELER.  The  model
having the lowest value of the MODELER objective function
was selected and was improved by energy minimization. The
stereochemical quality of the selected model was evaluated
using  the  PROCHECK  program  [17].  Swiss-Pdb  Viewer
[18]  was  used  for  structural  analyses  and  to  generate  the
p.M645I mutant model. ConSeq [19] and GetArea version
1.1 using a sphere probe radius of 1.4 Å [20] were used to
analyze solvent accessibility surface.
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sites  of  the  c.1935G>A  mutation,  splice  site  scores  were
predicted by the Neural Network Based Program and the
Splice View program.
Minigene constructs: To validate in silico prediction of the
impact of the c.1935G>A mutation on splicing, wild-type and
corresponding mutated genomic fragments were subcloned
into expression vectors p(13,17)/cytomegalovirus (CMV) and
transfected into HeLa cells. Amplification of MYO7A exon 16
and surrounding intronic sequences was performed using a
forward primer (5′-TGA GGT AAC CAA GTC CGA TTA
CTC CTT-3′) and a reverse primer (5′-GTG CTA GCG GGC
Figure 1. Pedigree and analysis of a Tunisian family segregating autosomal recessive hearing loss with variability in the diagnosis of retinitis
pigmentosa. A: Pedigree of a Tunisian family and haplotypes of polymorphic markers in the MYO7A region are shown. In pedigree, the square
symbol indicates male, the circle symbol denotes female and black symbol represents affected individuals. B: DNA chromatogram from a
control individual (bottom) and patient MB9 (top) are shown. Mutation consists on a homozygous mutation (G-A) at nucleotide 1935 located
in exon 16, resulting in a Met to Ile substitution at amino acid 645 of myosin VIIA. Asterisk indicates the position of the homozygous mutation.
C: Fundus photographs in 40-year-old (P1: MB9) and 47-year-old (P2: MB60) patients showed variability in the severity of retinitis pigmentosa
(RP). MB9 had a mild peripheral RP, while MB60 had only some pigments. D: Visual field test results obtained on the right (RE) and the left
(LE) eye of patient MB9 at the age of 40 years are shown. A series of random lights of different intensities are flashed in the peripheral field
of vision of the patient. When the patient perceives the computer generated light suddenly appearing in his or her field of view, the patient
presses a button to indicate a response. In the picture of the visual field a lighter gray spot is assigned. If the patient is unable to see the light
in an appropriate portion of the field of view, then we see on the computer a darker gray spot (Dot don’t see) indicating vision loss. Visual
field loss was severe in this patient. In fact, the nasal and temporal fields were not preserved and only the central field was maintained. Ganzfeld
electroretinogram (ERG) and visual-evoked potentials (VEP) of RE and LE of patient MB9 are shown. The ERG and the VEP test the function
of the visual pathway from the retina (ERG) to the occipital cortex (VEP). These tests were conducted by placing a standard ERG device
attached to the skin 2 mm above the orbit. VEPs were recorded simultaneously from an electrode attached to the occipital scalp 2 mm above
the region on the midsagittal plane. An electrode placed on the forehead provided a ground. The results can be directly related to the part of
a visual field that might be defective. This is based on the anatomic relationship of the retinal images and the visual field. After dark adaptation
for 30 min, the doctor places anesthetic drops in the patient's eye and places a contact lens on the surface of the eye. Once the contact lens is
in place, a series of blue, red, and white lights is shown to the patient. The VEP is an evoked electrophysiological potential that can be extracted,
using signal averaging, from the electroencephalographic activity recorded at the scalp. Both the ERG and VEP were differentially amplified
band pass filtered (0, 1, 30 Hz), recorded over 300 ms epochs, and signal averaged. The visual evoked potential to flash stimulation consists
of a series of negative and positive waves. The earliest detectable response has a peak latency of approximately 30 ms post stimulus. For the
flash VEP, the most robust components are the negative peak N2 and positive peak P2 peaks. Measurements of the P2 amplitude should be
made from the positive P2 peak at around 207.3 ms. The ERG recorded in MB9 showed an absence of responses. While the VEP showed a
normal response in both eyes. These traces confirm the evidence of a significant bilateral global retinal degeneration. Only cone flicker
responses of less than 15% of the normal mean were recordable under photopic conditions, while all other responses were below noise level,
a typical finding for patients with RP.
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1900ATC TGC AAG CAT TAC T-3′). Sequence mismatches were
introduced to create BstEII and NheI restriction sites (bold
letters). These primers led to an 892-bp PCR product. PCR
conditions were as follows: 5 min at 94 °C followed by 40
cycles, each consisting of 30 s at 94 °C, 30 s at 66 °C, and 50
s at 72 °C, then a final elongation at 72 °C for 10 min. The
PCR products were digested with BstEII and NheI restriction
endonucleases and inserted at the BstEII/NheI sites of the
splicing cassette p(13,17)/CMV that was designed to contain
the two adjacent constitutive exons 13 and 17 of the human
4.1R  gene  with  their  downstream  and  upstream  flanking
intron  sequences,  respectively  [21].  The  constructs  were
further  sequenced  to  ascertain  the  absence  of  additional
sequence changes.
Cell culture and transfection: HeLa cells were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen, Karlsruhe,
Germany)with 10% fetal calf serum in four well plates. Cells
were transfected with 2 μg of wild-type or mutated minigene
constructs, using FuGENE 6 Transfection Reagent (Roche
Diagnostics Ltd, Lewes, UK), according to the manufacturer’s
procedures. Briefly, a mixture of 95 μl of serum-free medium
and 3 µl of FuGENE® 6 was vortexed and incubated for 5
min at room temperature, then, we added 2 μg of plasmid DNA
into the tube. After incubation at room temperature, we added
the transfection reagent to the cells in a drop-wise manner.
Stably transfected cells were selected for 10–12 days in the
same  medium  containing  600–800  μg  Geneticin  G418/ml
(Invitrogen).
RNA  extraction  and  reverse  transcriptase-PCR  analysis:
HeLa  cells  were  washed  twice  with  Ca2+/Mg2+-free
phosphate-buffered  saline  (PBS;  1X),  collected  by
trypsinization, and centrifuged. Isolation of total RNA was
performed using TRIZOL reagents (Invitrogen), according to
the manufacturer’s protocol. RNA was reverse transcribed,
and cDNAs were used as templates for PCR amplification
using the forward and reverse primers within the cassette’s
upstream (UE, 4.1R exon 13) and downstream (DE, 4.1R exon
17) exons, as previously described [21]. Direct sequencing of
reverse transcriptase (RT)-PCR products was performed by
standard conditions.
The effect of a splice site mutation was also assessed by
RT–PCR analysis of lymphoid RNAs obtained from affected
and control individuals. Total RNA was isolated from 10 ml
of  blood  samples,  using  PureLink™  Micro-to-Midi  Total
RNA Purification System (Invitrogen). Reverse transcription
was performed using oligo-dT primers and 200 U of M-MuLV
(Moloney  Murine  Leukemia  Virus)  Reverse  Transcriptase
(Fermentas,  St.  Leon-Rot,  Germany).  The  PCR  step  was
performed using forward primer 5′-AGA CCC AGT TTG
GCA TCA AC-3′ (exon 14) and reverse primer 5′-ATT CCT
GAG TAC CGC AGC TGG-3′ (exon 17) and was expected
to yield a 346-bp fragment.
RESULTS
Clinical variability of retinitis pigmentosa within a family
segregating hearing loss: An audiometric test performed in
patients from the Tunisian family showed severe to profound
bilateral sensorineural HL. Deaf individuals who underwent
a caloric test had vestibular areflexia. Clinical interviews ruled
out  any  history  of  a  delay  in  the  age  of  walking.  The
ophthalmological  investigation  in  this  family  showed
variability in the clinical onset and diagnosis of RP among
patients. Individual MB9 (40 years old), her brother (37 years
old), and her uncle (77 years old) had similar mild RP (Figure
1). In these individuals, night blindness was reported in the
third decade. A visual field test and ERG was performed only
in individual MB9. The visual field (Goldmann targets III/4e)
was significantly reduced to a 5° concentric field and temporal
island fields for both eyes. The nasal and temporal fields were
not  preserved,  and  only  the  central  field  was  maintained
(Figure  1).  The  Ganzfeld-ERG  showed  an  almost  normal
response flash visual-evoked potential in both eyes and a
significant bilateral global retinal degeneration. Only cone
flicker responses of less than 15% of the normal mean were
recordable  under  photopic  conditions,  while  all  other
responses were below noise level, a typical finding for patients
with retinitis pigmentosa (Figure 1). Fundus examination of
MB9’s  non-consanguineous  husband  (47  years  of  age)
showed only a slight waxy pallor of the optic disc, so the
absence  of  severe  retinal  degeneration  as  indicated  by
thinning and loss of pigment epithelium. Their daughters (15
and 9 years old) did not show any anomaly in funduscopy.
A point mutation within MYO7A revealed by microsatellite
genotyping  and  nucleotide  sequencing:  In  an  attempt  to
identify the altered gene, we first performed a genetic linkage
analysis  of  fluorescent  dye-labeled  polymorphic
microsatellite markers covering all known loci for USH. This
analysis revealed evidence for a linkage to MYO7A mapping
to chromosome 11q13.5 (Figure 1). All affected individuals
showed  a  homozygous  haplotype.  Direct  sequencing  of
MYO7A in one affected individual revealed a G to A transition
(c.1935G>A) in the homozygous state. Co-segregation of the
transition with HL in the family was confirmed by PCR-
restriction fragment length polymorphism. This mutation is
located in the last position of exon 16 and would potentially
substitute an isoleucine for a methionine at position 645 of the
protein (p.M645I).
Single amino acid substitution would not alter myosin VIIa
function: A model covering the myosin motor domain from
residue Val2 to Gln752 was built using the crystal structure
of the myosin-II heavy chain from D. discoideum (PDB 1d0x,
2.0 Å resolution) as a template. The region encoded by exon
16 is located in the middle of this domain, which encodes the
HW helix, the third strand of the central seven-stranded β
sheet, and two loops (Figure 2). This portion of the protein is
highly conserved among myosin VIIA homologs and seems
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1901to play an important role in the communication between the
actin interface and nucleotide-binding pocket [22]. ConSeq
and GetArea results predict that p.Met645, which belongs to
a loop between the third strand of the central seven-stranded
β sheet and the SH2 helix, is a solvent-exposed residue. The
replacement of this solvent-exposed residue with isoleucine
does not perturb the native structure. In addition, this mutation
is quite distant from the nucleotide and actin-binding sites.
Altogether  these  predictions  did  not  support  a  major
functional impact of the amino acid substitution on protein
function.  We  therefore  hypothesized  that  the  genomic
mutation  must  have  rather  an  earlier  impact  on  mRNA
metabolism.
Nucleotide change weakens the 5′ splice site: The c.1935G>A
mutation occurs at the last position of exon 16. We used the
two splice site prediction programs Neural Network Splice
Site Prediction Tool and Splice view to evaluate the strength
of the altered splice site. The wild-type sequence resulted in
predicted scores of 0.92 and 0.90, while the calculated values
of the numerical score for the altered sequence were 0.62 and
0.60, respectively. These data suggest a weakening of the exon
16 donor site caused by the c.1935G>A mutation.
Single nucleotide mutation enhances exon 16 exclusion: To
investigate  the  possible  effect  of  the  mutation  on  mRNA
splicing,  we  performed  an  RT–PCR  analysis  of  total
lymphocyte  RNA  obtained  from  the  patient.  The  control
sample displayed an expected band of 346 bp, containing
exons 14 to 17. An additional faint band appeared in the
control; it corresponded to an mRNA species missing exon 16
(Figure 3). This pattern was consistently encountered in six
tested control individuals (data not shown). This observation
suggests that exon 16 must be alternatively spliced, at least in
lymphocytes.  In  the  patient  however,  the  splicing  pattern
showed rather a predominant exclusion of the exon (Figure
3).
To  know  if  the  altered  splicing  is  due  to  the  unique
mutation found in exon 16, we used a transfected minigene
approach to address the functional impact of the c.1935G>A
mutation on exon 16 splicing. A genomic fragment of 892 bp
containing  exon  16  and  flanking  intron  15  and  intron  16
sequences  was  cloned  into  an  efficient  splicing  cassette.
Control  and  mutated  minigene  constructs  were  stably
transfected in HeLa cells. RT–PCR analysis performed on
total  RNA  extracted  from  transfected  cells  faithfully
reproduced  the  effects  observed  in  vivo  (Figure  3).  The
minigene splicing pattern obtained from the normal construct
revealed  a  major  374-bp  fragment,  and  a  minor  246-bp
product.  The  mutated  construct  also  displayed  the  two
different transcripts, with a predominant shorter band of 246
bp and a faint 374-bp fragment. The proportion (%) of mis-
spliced transcripts compared to the full-length transcript was
62%. The percentage was measured using the Quantity One
software (Bio-Rad, Marnes-La-Coquette, France; Figure 3).
Direct sequencing revealed that the 374 bp contains exon 16,
whereas the 246-bp PCR product is lacking the exon. These
results strongly suggest that the unique c.1935G>A nucleotide
change alters MYO7A pre-mRNA splicing and results in a
switch from predominant inclusion to predominant skipping
of exon 16.
Exon 16 skipping leads to the loss of the HW helix and
the third strand of the central seven-stranded β sheet. The HW
Figure 2. Homology model of human
myosin  VIIA  showing  the  exon  16-
encoded peptide in green in the middle
of the motor domain, which is colored
in orange. This exon encodes the HW
helix [22], the third strand of the central
seven-stranded  β-sheet,  and  the
associated loops. Wild-type methionine
and  mutant  isoleucine  645  residues
before  the  SH2  helix  (in  orange)  are
represented as sticks and highlighted in
green  and  magenta,  respectively.
Structure visualization was done using
Pymol software.
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1902helix contains the actin-binding motif, and the strand is part
of the central β sheet or transducer region, which concerted
distortion led to conformational changes of the motor domain.
Therefore, deletion of exon 16 would most likely affect the
conformation of MYO7A and would result in a functionally
altered allele.
DISCUSSION
The presence of RP is the crucial trait differentiating Usher
syndrome from nonsyndromic HL. RP is defined simply as a
progressive retinal dystrophy, identifiable by defective dark
adaptation or nyctalopia (night blindness), reduction of the
peripheral visual field (known as tunnel vision), appearance
of “bony spicule” in the retina revealed by fundoscopy, and
an  abnormal  or  nonrecordable  ERG  [23].  Five  autosomal
recessive nonsyndromic HL (DFNB2) families with MYO7A
mutations  were  reported.  In  the  Chinese,  Iranian,  and
Pakistani families, the affected adults (>25 years of age) who
had ophthalmologic examinations were almost normal [10,
Figure 3. Exon 16 splicing pattern associated with the c.1935G>A mutation. A: Analysis of endogenous RNA from lymphoid cells. We
amplified a 346-bp fragment from exon 14 to exon 17 of MYO7A in a healthy control individual. An additional faint band appeared in the
control; it corresponded to an mRNA species missing exon 16 (lane 2). In patient MB9, the splicing pattern showed a predominant exclusion
of exon 16 (lane 1). Lane 3 refers to negative control and M indicates size marker. Direct sequencing of these two different transcripts revealed
that a shorter band of 246 bp corresponds to an abnormal transcript without exon 16, whereas the other band of 374 bp corresponds to a normal
transcript that contains exon 16.   B:  Ex  vivo  splicing  assays  were  performed.  Wild-type and  mutant constructs  were stably transfected in 
HeLa  cells,  and  the  exon 16  splicing  pattern  was  analyzed  by  reverse  transcription-polymerase  chain  reaction.  Consistent  with  data 
presented in A,  exon 16 is  predominantly  included from  the wild-type construct (lane 1).  The c.1935G>A mutation  at the end  of exon 16 
resulted  in  massive  skipping  of  the  exon  (lane 2).  Lane 3 refers  to  negative  control  and M indicates size marker. UE and DE refer to 
upstream and downstream exons of the cassette, respectively.
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190313,24]. Only one deaf patient (41 years old) in the Pakistani
DFNB2 family had slightly subnormal rod and cone responses
and a suboptimal quality ERG. However, RP in the Iranian
DFNB2 family was ruled out by funduscopy excluding severe
but not mild RP. The Tunisian family that enabled the defining
of the DFNB2 locus was diagnosed with HL and vestibular
dysfunction in 1994, but when reassessed 7 years later, five
of 12 adult patients (>25 years of age) were found to have mild
RP [25]. The clinical presentation of the Tunisian family we
describe in this report is noteworthy because of its similarity
to  the  unrelated  Tunisian  DFNB2  family  reported  earlier
[25].
To date, over 130 recessive mutations in MYO7A have
been identified and are listed in the Human Gene Mutation
Database.  Almost  all  known  MYO7A  mutations  cause
USH1B. Six variations were described in five families with
autosomal  recessive  nonsyndromic  HL.  In  the  Pakistani
DFNB2 family, a correlation of clinical phenotype with the
molecular phenotype was observed based on a myosin VIIa
intracellular targeting assay. Riazuddin et al. [13] showed that
the p.E1716del mutation of myosin VIIa has residual function
in the inner ear. However, variations identified in the Chinese
and  the  Iranian  DFNB2  families  did  not  document  a
relationship between the type and location of the MYO7A
mutations in USH1B and recessive nonsyndromic phenotype.
In  the  Chinese  family  designated  DFNB.05,  affected
individuals are compound heterozygotes for a splice acceptor
consensus site mutation (c.19–2A4G) in intron 3, and a T
insertion mutation in exon 28 (p.V1199fsX1228) of MYO7A
[24,25]. Both of these mutations are predicted to result in
premature  translation  termination,  and  to  date  all  such
predicted truncating alleles of MYO7A gene are associated
with USH. The p.R244 residue, affected in the Chinese family
DFNB.01, is located near the open edge of the large cleft
separating the upper 50 kDa from the lower 50K domain
[26]. The cleft is thought to close upon binding to actin and
open upon dissociation. Introduction of a proline would alter
the ability of the cleft to open and close properly upon binding
to  actin.  Proline  would  also  disrupt  the  hydrogen  bond
between p.R244 and p.D396 amino acids. The GFP-tagged
mouse ortholog of p.R244P (GFP-myosin VIIa [p.R233P])
showed little or no GFP fluorescence within stereocilia, as
observed  for  mutations  associated  with  USH1  [13].  The
p.R395H mutation described in the Iranian DFNB2 family
affects a residue immediately adjacent to the p.D396. The
p.R395 residue, located in the motor domain of myosin VIIa,
is exposed and highly conserved across species. The p.R395H
mutation  induced  a  local  change  in  charge  that  likely
compromises  the  structure  and/or  function  of  the  motor
domain. The p.R395 and p.D396 residues are adjacent to
p.A397.  Watanabe  et  al.  [27]  showed  that  the  p.A397D
missense mutation associated with USH abolished the actin-
activated ATPase activity completely.
In the Tunisian DFNB2 families, the mutation lies at the
last nucleotide of exon 16 of the MYO7A gene. Modeling
analysis has led us to predict that the resultant amino acid
change does not impair the structure and the activity of the
protein.  RNA  analyses  revealed  that  exon  16  is  slightly
excluded in control lymphocytes and that the c.1935G>A
mutation triggers enhanced exon skipping. This finding is
consistent with our hypothesis that c.1935G>A causes a less
severe  molecular  phenotype  than  the  USH1B-associated
alleles. In a mice model Schwander et al. [28] showed that the
(c.5742+5G>A)  mutation,  which  affects  splicing  of  the
MYO7A transcript and truncates the myosin VIIa tail domain,
leads to tissue-specific effects on protein levels. In the inner
ear, expression of truncated myosin VIIa is severely reduced,
whereas in RPE cells, the truncated myosin VIIa is expressed
at levels similar to the wild-type protein level.
Previous  works  have  reported  four  MYO7A  variants
localized  at  the  last  position  of  an  exon  affecting  the  G
nucleotide at position −1 of donor splice sites. Thus c.592G>A
(p.Ala198Thr),  c.1687G>A  (p.G563S),  (c.3503G>C
(p.Arg1168Pro),  and  c.5944G>A  (p.Gly1982Arg)  were
described  in  families  with  USH1B.  All  these  sequence
variations were shown to globally weaken the natural 5′ splice
site and to induce aberrant splicing. Transcripts resulting from
the c.1687G>A mutation were undetectable [29]. Minigene
studies revealed that c.592G/A, c.3503G/C, and c.5944G/A
variants are associated with moderate to high levels of exon
skipping  [30].  The  percentages  of  mis-spliced  transcripts
compared to the full-length transcript were respectively 76,
62, and 100%. Although exon skipping is partial in c.592G/A
and  c.3503G/C  mutations  and  comparable  to  what  we
described in Tunisian families, they result in a more severe
phenotype. This can be explained by the fact that they occur
in compound heterozygotes with a missense p.G163R and a
nonsense p.R150X mutation, respectively. These mutations
also result in out-of-frame splice products, which would elicit
the  altered  mRNA  to  degradation  by  Nonsense-Mediated
mRNA Decay (NMD) [31], whereas the c.1935G>A mutation
results inLQframe transcript.
In this study, we established that the c.1935G>A mutation
identified  in  Tunisian  families  with  HL  and  variable
expression of RP results in the partial skipping of exon 16. We
conclude that the residual function of myosin VIIa may result
in DFNB or Usher phenotypes. Other environmental and/or
genetic factors might have an impact on the RP phenotype. In
this regard, subtle variations in splicing regulation have been
recently emphasized regarding the use of the 5′ splice sites
[32,33].
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